Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Actinic (Solar) Keratosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H1 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects - The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Actinic (Solar) Keratosis Overview 9 Therapeutics Development 10 Pipeline Products for Actinic (Solar) Keratosis - Overview 10 Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11 Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12 Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 14 Actinic (Solar) Keratosis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Actinic (Solar) Keratosis - Products under Development by Companies 19 Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 21 Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 22 3M Drug Delivery Systems 22 Athenex, Inc. 23 Biofrontera AG 24 Digna Biotech, S.L. 25 Dolorgiet Gmbh & Co. Kg 26 Foamix Pharmaceuticals Ltd. 27 G&E Herbal Biotechnology Co., Ltd. 28 Galderma S.A. 29 Laboratories Ojer Pharma S.L. 30 LEO Pharma A/S 31 Novartis AG 32 Novelix Pharmaceuticals, Inc. 33 Oncology Research International Limited 34 Promius Pharma, LLC 35 SkyePharma Plc 36 Spherium Biomed S.L. 37 Valeant Pharmaceuticals International, Inc. 38 Actinic (Solar) Keratosis - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Combination Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 ACT-01 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 AD-17137 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AK-3012 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 aminolevulinic acid hydrochloride - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 celecoxib - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 DFD-08 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 disitertide - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 hydrogen peroxide + sulindac - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 IDP-125 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 IDP-128 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 imiquimod - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 imiquimod SR - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 KX-01 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 LEO-43204 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 LFX-453 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 NVX-207 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ORIL-007 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 resiquimod - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 SKP-024 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecule to Agonize TLR-7 and TLR-8 for Oncology, Allergic Rhinitis, Actinic Keratosis and Warts - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecules to Activate Protein Kinase C for Dermatology and Oncology - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 SP-12054 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 SRT-100 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 VPE-001 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Actinic (Solar) Keratosis - Recent Pipeline Updates 79 Actinic (Solar) Keratosis - Dormant Projects 85 Actinic (Solar) Keratosis - Discontinued Products 87 Actinic (Solar) Keratosis - Product Development Milestones 88 Featured News & Press Releases 88 Feb 11, 2016: Biofrontera Announces, Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer 88 Jan 26, 2016: FDA completes Biofrontera's Ameluz NDA mid-cycle review 89 Dec 07, 2015: Swissmedic grants marketing approval for Ameluz in Switzerland 89 Oct 02, 2015: FDA determines May 10, 2016 as PDUFA date for Ameluz 89 Sep 22, 2015: Excellent long-term outcome with field treatment of actinic keratosis with Ameluz 90 Jun 22, 2015: Biofrontera completes final steps ahead of FDA New Drug Application in the USA 91 May 06, 2015: Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication 91 Mar 25, 2015: Biofrontera starts Sales and Marketing of Ameluz in Spain 92 Jan 26, 2015: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz 92 Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 93 Appendix 94 Methodology 94 Coverage 94 Secondary Research 94 Primary Research 94 Expert Panel Validation 94 Contact Us 94 Disclaimer 95
List of Tables
Number of Products under Development for Actinic (Solar) Keratosis, H1 2016 10 Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H1 2016 22 Actinic (Solar) Keratosis - Pipeline by Athenex, Inc., H1 2016 23 Actinic (Solar) Keratosis - Pipeline by Biofrontera AG, H1 2016 24 Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H1 2016 25 Actinic (Solar) Keratosis - Pipeline by Dolorgiet Gmbh & Co. Kg, H1 2016 26 Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 27 Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 28 Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H1 2016 29 Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma S.L., H1 2016 30 Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2016 31 Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2016 32 Actinic (Solar) Keratosis - Pipeline by Novelix Pharmaceuticals, Inc., H1 2016 33 Actinic (Solar) Keratosis - Pipeline by Oncology Research International Limited, H1 2016 34 Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H1 2016 35 Actinic (Solar) Keratosis - Pipeline by SkyePharma Plc, H1 2016 36 Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H1 2016 37 Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 38 Assessment by Monotherapy Products, H1 2016 39 Assessment by Combination Products, H1 2016 40 Number of Products by Stage and Target, H1 2016 42 Number of Products by Stage and Mechanism of Action, H1 2016 44 Number of Products by Stage and Route of Administration, H1 2016 46 Number of Products by Stage and Molecule Type, H1 2016 48 Actinic (Solar) Keratosis Therapeutics - Recent Pipeline Updates, H1 2016 79 Actinic (Solar) Keratosis - Dormant Projects, H1 2016 85 Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H1 2016 86 Actinic (Solar) Keratosis - Discontinued Products, H1 2016 87
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
